James Clemmer - AngioDynamics President CEO, Director

ANGO Stock  USD 5.87  0.17  2.98%   

CEO

Mr. James C. Clemmer is President, Chief Executive Officer, Director of the Company. Prior to joining AngioDynamics, Mr. Clemmer served as President of the 1.8 billion medical supplies segment at Covidien plc. where he directed the strategic and daytoday operations for global business divisions that collectively manufactured 23 different product categories. In addition, he managed global manufacturing, research and development, operational excellence, business development and all other functions associated with the medical supplies business. Prior to his role at Covidien, Mr. Clemmer served as Group President at Kendall Healthcare, where he managed the U.S. business across five divisions and built the strategic plan for the medical supplies segment before it was spun off from Tyco. Mr. Clemmer began his career at Sage Products, Inc. Mr. Clemmer currently serves on the Board of Directors for AngioDynamics and Lantheus Medical Imaging. Mr. Clemmer is a graduate of the Massachusetts College of Liberal Arts, where he served as interim president from August 2015 until March 1, 2016. since 2016.
Age 60
Tenure 8 years
Address 14 Plaza Drive, Latham, NY, United States, 12110
Phone518 795 1400
Webhttps://www.angiodynamics.com

AngioDynamics Management Efficiency

The company has return on total asset (ROA) of (0.0286) % which means that it has lost $0.0286 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0349) %, meaning that it created substantial loss on money invested by shareholders. AngioDynamics' management efficiency ratios could be used to measure how well AngioDynamics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of March 2024, Return On Capital Employed is likely to grow to -0.05. In addition to that, Return On Assets is likely to drop to -0.11. At this time, AngioDynamics' Other Assets are very stable compared to the past year. As of the 29th of March 2024, Other Current Assets is likely to grow to about 4.5 M, while Total Assets are likely to drop about 533.4 M.
The company currently holds 49.82 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. AngioDynamics has a current ratio of 2.23, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist AngioDynamics until it has trouble settling it off, either with new capital or with free cash flow. So, AngioDynamics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AngioDynamics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AngioDynamics to invest in growth at high rates of return. When we think about AngioDynamics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 5 records

CEO Age

Andrew AstorNephros
67
Adam LevyNexGel Warrant
61
Robert BanksNephros
N/A
Daron EvansNephros
50
Nathan HardingEkso Bionics Holdings
46
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access and for use in oncology and surgical settings in the United States and internationally. The company was founded in 1988 and is headquartered in Latham, New York. Angiodynamics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 760 people. AngioDynamics (ANGO) is traded on NASDAQ Exchange in USA. It is located in 14 Plaza Drive, Latham, NY, United States, 12110 and employs 815 people. AngioDynamics is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

AngioDynamics Leadership Team

Elected by the shareholders, the AngioDynamics' board of directors comprises two types of representatives: AngioDynamics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AngioDynamics. The board's role is to monitor AngioDynamics' management team and ensure that shareholders' interests are well served. AngioDynamics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AngioDynamics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Ben Davis, Senior Vice President Business Development
Michael Trimarchi, Interim CFO, VP and Global Controller
Jeffrey Gold, Independent Director
Chad Campbell, Senior Vice President and General Manager, Vascular Access
Steven Laporte, Independent Director
David Helsel, Senior Vice President - Global Operations
Jan Reed, Director
Dennis Meteny, Independent Director
Eileen Auen, Director
Wesley Johnson, Independent Director
Mark Stephens, Sr. VP of Admin.
Stephen Trowbridge, Sr. VP, General Counsel and Assistant Secretary
Heather DanielsCariveau, Senior Vice President-Human Resources
Saleem Cheeks, Vice Communications
John Soto, Chief Commercial Officer and Executive VP
Benjamin Davis, Senior Vice President Business Development
Barbara Kucharczyk, Senior Vice President-Global Operations
Robert Simpson, Senior Vice President and General Manager, Peripheral Vascular
Kevin Gould, Independent Director
Michael Greiner, CFO, Executive Vice President
Laura Piccinini, Senior International
Warren Nighan, Senior Vice President-Senior Vice President Quality & Regulatory Affairs
Sriram Venkataraman, Independent Director
Brent Boucher, Senior Vice President and General Manager, Oncology/Surgery
Joseph DeVivo, CEO and President and Director
Scott Centea, Senior Therapies
James Clemmer, President CEO, Director
Caitlin Stefanik, IR Contact Officer
Richard Rosenzweig, Gen VP
Christopher Dailey, IR Contact Officer
Marna BronfenMoore, Senior Resources
Kim Seabury, Senior Vice President Information Technology
Juan Serna, Senior Affairs
Karen Licitra, Independent Director
Gary Barrett, Senior Vice President Quality and Regulatory Affairs
David Burgstahler, Independent Director
Howard Donnelly, Independent Chairman of the Board

AngioDynamics Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AngioDynamics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with AngioDynamics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AngioDynamics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AngioDynamics will appreciate offsetting losses from the drop in the long position's value.

Moving together with AngioDynamics Stock

  0.62MBOT Microbot Medical Earnings Call TodayPairCorr
  0.85NEOG Neogen Report 4th of April 2024 PairCorr

Moving against AngioDynamics Stock

  0.79BSX Boston Scientific Corp Financial Report 24th of April 2024 PairCorr
  0.79CLVRW Clever Leaves HoldingsPairCorr
  0.72PNTG Pennant Group Financial Report 2nd of May 2024 PairCorr
  0.62RDNT RadNet Inc Financial Report 14th of May 2024 PairCorr
  0.56COO Cooper Companies Financial Report 6th of June 2024 PairCorr
The ability to find closely correlated positions to AngioDynamics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AngioDynamics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AngioDynamics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AngioDynamics to buy it.
The correlation of AngioDynamics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AngioDynamics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AngioDynamics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AngioDynamics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether AngioDynamics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AngioDynamics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Angiodynamics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Angiodynamics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.
Note that the AngioDynamics information on this page should be used as a complementary analysis to other AngioDynamics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Complementary Tools for AngioDynamics Stock analysis

When running AngioDynamics' price analysis, check to measure AngioDynamics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioDynamics is operating at the current time. Most of AngioDynamics' value examination focuses on studying past and present price action to predict the probability of AngioDynamics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AngioDynamics' price. Additionally, you may evaluate how the addition of AngioDynamics to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Stocks Directory
Find actively traded stocks across global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Is AngioDynamics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.36)
Revenue Per Share
8.28
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.03)
Return On Equity
(0.03)
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.